Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions
Background:. Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells. We compared the efficacy of sarpogrelate-based dual antiplatelet therapies for the prevention of resten...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2015-06-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.4103/0366-6999.158285 |
| _version_ | 1797646844628566016 |
|---|---|
| author | Yue-Xin Chen Wen-Da Wang Xiao-Jun Song Yong-Quan Gu Hong-Yan Tian He-Jie Hu Ji-Chun Zhao Xiao-Qiang Li Chang-Wei Liu |
| author_facet | Yue-Xin Chen Wen-Da Wang Xiao-Jun Song Yong-Quan Gu Hong-Yan Tian He-Jie Hu Ji-Chun Zhao Xiao-Qiang Li Chang-Wei Liu |
| author_sort | Yue-Xin Chen |
| collection | DOAJ |
| description | Background:. Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells. We compared the efficacy of sarpogrelate-based dual antiplatelet therapies for the prevention of restenosis and target lesion revascularization (TLR) rates comparing with that of clopidogrel after percutaneous endovascular interventions (EVIs) of femoropopliteal (FP) arterial lesions.
Methods:. This prospective, multicenter, randomized clinical trial recruited a total of 120 patients with successful EVI of FP lesions at seven centers across China between January 2011 and June 2012. Patients were randomized to receive either sarpogrelate (100 mg trice daily for 6 months, n = 63) or clopidogrel (75 mg once daily for 6 months, n = 57). All patients also received oral aspirin (100 mg once daily for 12 months). Clinical follow-up was conducted up to 12 months postprocedure.
Results:. There was no significant difference between the two groups in basic demographic data. The restenosis rate was higher in the clopidogrel group (22.80%) than in sarpogrelate group (17.50%), but there was no significant difference between these two groups (P = 0.465). The TLR rate, ipsilateral amputation rate, mortality in all-cause and bleeding rate were also similar in the two groups (P > 0.05).
Conclusions:. Aspirin plus sarpogrelate is a comparable antithrombotic regimen to aspirin plus clopidogrel after EVI of FP arterial lesions. Dual antiplatelet therapies might play an important role in preventing restenosis after successful EVI of FP lesions. |
| first_indexed | 2024-03-11T15:08:38Z |
| format | Article |
| id | doaj.art-40a899b1acb84979891e46864ad62713 |
| institution | Directory Open Access Journal |
| issn | 0366-6999 2542-5641 |
| language | English |
| last_indexed | 2024-03-11T15:08:38Z |
| publishDate | 2015-06-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj.art-40a899b1acb84979891e46864ad627132023-10-30T03:37:28ZengWolters KluwerChinese Medical Journal0366-69992542-56412015-06-01128121563156610.4103/0366-6999.158285cm9-128-1563Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular InterventionsYue-Xin Chen0Wen-Da Wang1Xiao-Jun Song2Yong-Quan Gu3Hong-Yan Tian4He-Jie Hu5Ji-Chun Zhao6Xiao-Qiang Li7Chang-Wei Liu81 Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100068, China1 Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100068, China1 Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100068, China2 Department of Vascular Surgery, Peking XuanWu Hospital, Beijing 100053, China3 Department of Vascular Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China4 Department of Vascular Surgery, Anhui Provincial Hospital, Hefei, Anhui 230001, China5 Department of Vascular Surgery, West China Hospital, Chengdu, Sichuan 510100, China6 Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China1 Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100068, ChinaBackground:. Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells. We compared the efficacy of sarpogrelate-based dual antiplatelet therapies for the prevention of restenosis and target lesion revascularization (TLR) rates comparing with that of clopidogrel after percutaneous endovascular interventions (EVIs) of femoropopliteal (FP) arterial lesions. Methods:. This prospective, multicenter, randomized clinical trial recruited a total of 120 patients with successful EVI of FP lesions at seven centers across China between January 2011 and June 2012. Patients were randomized to receive either sarpogrelate (100 mg trice daily for 6 months, n = 63) or clopidogrel (75 mg once daily for 6 months, n = 57). All patients also received oral aspirin (100 mg once daily for 12 months). Clinical follow-up was conducted up to 12 months postprocedure. Results:. There was no significant difference between the two groups in basic demographic data. The restenosis rate was higher in the clopidogrel group (22.80%) than in sarpogrelate group (17.50%), but there was no significant difference between these two groups (P = 0.465). The TLR rate, ipsilateral amputation rate, mortality in all-cause and bleeding rate were also similar in the two groups (P > 0.05). Conclusions:. Aspirin plus sarpogrelate is a comparable antithrombotic regimen to aspirin plus clopidogrel after EVI of FP arterial lesions. Dual antiplatelet therapies might play an important role in preventing restenosis after successful EVI of FP lesions.http://journals.lww.com/10.4103/0366-6999.158285 |
| spellingShingle | Yue-Xin Chen Wen-Da Wang Xiao-Jun Song Yong-Quan Gu Hong-Yan Tian He-Jie Hu Ji-Chun Zhao Xiao-Qiang Li Chang-Wei Liu Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions Chinese Medical Journal |
| title | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions |
| title_full | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions |
| title_fullStr | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions |
| title_full_unstemmed | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions |
| title_short | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions |
| title_sort | prospective randomized study of sarpogrelate versus clopidogrel based dual antiplatelet therapies in patients undergoing femoropopliteal arterial endovascular interventions |
| url | http://journals.lww.com/10.4103/0366-6999.158285 |
| work_keys_str_mv | AT yuexinchen prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions AT wendawang prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions AT xiaojunsong prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions AT yongquangu prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions AT hongyantian prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions AT hejiehu prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions AT jichunzhao prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions AT xiaoqiangli prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions AT changweiliu prospectiverandomizedstudyofsarpogrelateversusclopidogrelbaseddualantiplatelettherapiesinpatientsundergoingfemoropoplitealarterialendovascularinterventions |